Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Missed loading up @ 1.22 WTF!!! I will definitely load this one up tomorrow promise!! Damn $$$$$
Not sure I like the news or not. Sure, they get $ from Sanofi...but they also lose the partnership..why?
Run based on some momo and short covering...? Will be interesting to see what unfolds going forward.
looks like they loaded somebody up with 20K @ 2.08
News: $LXRX Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for Zynquista TM (sotagliflozin) will be presented at the upcoming European Association for the Study of Diabetes (EASD) 55 th annual meeting (Sept...
In case you are interested LXRX - Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting
News: $LXRX Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of Zynquista TM (sotagliflozin) and the settlement of its related disputes with S...
Find out more LXRX - Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
News: $LXRX Active Stock among hottest- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
On Tuesday, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reached at $1.32 price level during last trade its distance from 20 days simple moving aver...
Find out more Active Stock among hottest- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
* * $LXRX Video Chart 08-09-2019 * *
Link to Video - click here to watch the technical chart video
Thanks, super new at this and took a big hit initially but am slowly making gains day by day,
Nice. Your first post was a winner.
shes going to blow!!!
zyquista had great results, look at the strong green afterhours!!!
* * $LXRX Video Chart 07-29-2019 * *
Link to Video - click here to watch the technical chart video
O/S: 330 Million Worthless shares Dumping!
LXRX, phase 3 trial Failed. It's finished. Might go bankruptcy! The MM's are holding it at this level in Order to Dump all their worthless shares before BK.
Be very careful.
$2’ easy this week from here. Congrats to new investors and sorry for old ones. Absolute steal here in 1’s
Down to $2 and nobody's posted anything here since May. Another USELESS IHUB board
Massive Squeeze above The 7.00 Threshold!!! $$$$ BOOM it Baybeeee $$$$
6.94 $$$$ $35.00 Price Target, People with diabetes are two to four times more likely to have heart disease (more than 77,000 deaths due to heart disease annually). ... People with diabetes are two to four times more likely to suffer a stroke. Blindness due to diabetic retinopathy. Each year 12,000 to 24,000 people lose their sight because of diabetes.
Go Full Blast Buying now @ 6.70 Lets Go Baybeeee!!! $$$$
Nice & Quiet here while LXRX exploding up 6% LOL Perfect Storm!!!
This Baby will be like TNDM back when price was still around 5.00 five yrs ago, we all know TNDM exploded to $74.81 $$$$$
Im Fully Loaded from 5.90 for the Explosion to $8.00 - $10.00 Soon!!! Then $35.00 Longterm Target!, Good Luck to me $$$$
Better Go all in now @ 6.00 The 300 Min Tic Chart crossing over!!! BOOM $$$$ $35.00 Soon
This should be trading , around $35.00 Already look at TNDM exploding @ 62.10 LXRX Float is 50% more than TNDM so $35.00 is the real valuation on this $$$
5.97 and Climbing This will Retest 8.39 on this Run, Then Explode to $34.00 Target Very Soon promise!! $$$
Added 10K more from 5.93 MMs Loading up for the Break Above 7.00 This week $$$
Major Explosion All Set above 6.20 Tic Toc Tic Toc, FOMO begins when price crosses above 6.20 Watch Out Above Baby! $$$$$
This will Explode like TNDM, Fully Loaded to the Top from 5.80 $$$$$ BOOM $$$$[/b]
Analyst Price Target $34.00 Lexicon Pharmaceuticals announces earnings. ($0.21) EPS. Beats estimates. $9.20m revenue
News: $LXRX LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company")(NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securitie...
Got this from https://marketwirenews.com/news-releases/lead-plaintiff-deadline-alert-faruqi-faruqi-llp-encourages-investors-who-suffered-losses-exceeding-100-000-investing-in-lexicon-pharmaceuticals-inc-to-contact-the-firm-7914028.html
LXRX on watch for tomorrow. This can go either way, but I'm thinking green.
News: $LXRX Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update
XERMELO ® (telotristat ethyl) 2018 U.S. Net Sales Reached $25.0 Million Sotagliflozin in Type 1 Diabetes: March 22 PDUFA Date in U.S., European Commission Decision Expected in Q2 2019 Following Recently-Received Positive CHMP Opinion THE WOODLANDS, Texas, March 13, 2019 (GL...
Got this from https://marketwirenews.com/news-releases/lexicon-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-a-business-update-7833940.html
* * $LXRX Video Chart 03-01-2019 * *
Link to Video - click here to watch the technical chart video
Stopped out again....LOL
LXRX sub $5
Re-entry here at 5.20 seems overdone and it was only a panel board rec.
Nice buy good entry! I got out at 11 haven't been following this since I sold it.
Back in again at 8.11 here on morning downgrade ....been fun so far
Been watching only have a few left darn it
Followers
|
55
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
770
|
Created
|
02/27/05
|
Type
|
Free
|
Moderators |
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.
In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.
The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.
“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |